What do systematic reviews say?

Intestinal trefoil factor (ITF), oral spray vs placebo

Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  RR 0.22 [0.10, 0.48]
  1 study · 99 participants
  GRADE not reported

Transforming growth factor-beta(2) (TGF-beta2) vs placebo

Transforming growth factor-beta(2) (TGF-beta2) showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  RR 0.10 [0.01, 1.71]
  1 study · 13 participants
  GRADE not reported

Intestinal trefoil factor (ITF), oral spray vs placebo

Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  RR 0.52 [0.35, 0.79]
  1 study · 99 participants
  GRADE not reported

Intestinal trefoil factor (ITF), oral spray vs placebo

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  Adverse events narratively reported (not GRADE-rated)
  1 study
  GRADE not reported

Intestinal trefoil factor (ITF), lower dose (336 mg) vs Intestinal trefoil factor (ITF), higher dose (2688 mg)

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  Insufficient evidence to determine whether lower (336 mg) or higher (2688 mg) dose performs better (Analyses 11.1 to 11.3); no pooled estimate reported
  1 study · 66 participants
  GRADE not reported

Intestinal trefoil factor (ITF), oral spray vs placebo

Intestinal trefoil factor (ITF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  RR 1.52 [0.06, 36.39]
  1 study · 99 participants
  GRADE not reported

LongoVital (herbal plus vitamin component) vs LongoVital (herbal component alone)

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  4 months
  A single trial at high risk of bias (Kolseth 2005) randomised participants to the herbal component of LongoVital alone or LongoVital with herbal plus vitamin component. Data presented as medians with 95% CIs,…
  1 study · 40 participants
  GRADE not reported

COE with blood/salivary (biomarker) analysis vs Conventional oral examination (COE) alone

The review found no eligible studies for this question.

• Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy… 2021 · Cochrane All outcomes
  No eligible studies; planned comparative analysis (COE vs COE with blood/salivary analysis) not populated in this version.
  0 studies
  No studies found

COE with vital rinsing (toluidine blue/tolonium chloride) vs Conventional oral examination (COE) alone

• Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy… 2021 · Cochrane All outcomes
  Sensitivity 0.40 [0.05, 0.85]
  1 study · 4080 participants
  Moderate